ibutilide
Trade name: corvert
Approved
Dec 28, 1995
Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels. Ibutilide is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Ibutilide is marketed as Corvert by Pfizer. — NCATS
Clinical trial activity
8 trials · 12 clinical orgs · 7 marketing orgs
Earliest trial started Oct 1, 2007 (NCT00589992)
Timeline
1990s
- Dec 28, 1995
Pharmacia & Upjohn — Earliest FDA Approval
- Dec 28, 1995
Pfizer — Marketing Organization
- Dec 28, 1995
Pharmacia & Upjohn — NDA Organization
- Dec 28, 1995
Pfizer — NDA Secondary Org
2010s
- Jan 11, 2010
Lutipold — Marketing Organization
- Jan 11, 2010
Mylan — Marketing Organization
- Jan 11, 2010
Daiichi Sankyo — Marketing Organization
- Jan 11, 2010
PHARMOBEDIENT — Marketing Organization
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
2020s
- Apr 1, 2024
Avet Lifesciences — Marketing Organization
Indications
Approved for
Mechanism of action
- HERGBLOCKER
KCNH2 blocker
Approval history
- approvedDec 28, 1995
Chemistry & pharmacology
SMILES
CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O- Mol. weight
- 885.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2355456 ↗
- WikipediaIbutilide ↗
- NCATS2436VX1U9B ↗
- ChEMBLCHEMBL533 ↗
- ChEMBLCHEMBL1200564 ↗
Also known as
- corvert
- corvert
- corvert
- corvert
- ibutilid
- ibutilid
- ibutilida
- ibutilida
- ibutilide
- ibutilide
- ibutilide
- ibutilide
- ibutilide
- ibutilide
- ibutilide
- ibutilide
- ibutilide fumarate
- ibutilide fumarate
- ibutilide fumarate
- ibutilide fumarate
- ibutilide fumarate
- ibutilide, fumarate salt (2:1), (+-)-isomer
- ibutilide, fumarate salt (2:1), (+)-isomer
- ibutilide, (-)-isomer
- ibutilide, (+-)-isomer
- ibutilide, (+)-isomer
- ibutilidum
- ibutilidum
- n-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide
- n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
- n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
- u-70226e
- u-70226e
- u82208e
- u-82208e
- u82209e
- u82209e
- u82209e
- u82209e
- u82209e
- u82209e
- u 82209e
- u-82209e
- u-82209e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04675788 | Phase 4 | Jan 4, 2021 | Cedars-Sinai Medical Center, Harvard University, Indiana University, National Heart, Lung, and Blood Institute (NHLBI), Purdue University |
| NCT03834883 | Phase 4 | Mar 26, 2019 | American Heart Association, Indiana University, Purdue University |
| NCT03370536 | N/A | Nov 1, 2017 | Icahn School of Medicine at Mount Sinai, Medtronic |
| NCT02513940 | Phase 4 | May 1, 2016 | American Heart Association, Indiana University, Purdue University |
| NCT01929083 | Phase 2 | Apr 1, 2013 | American Heart Association, Indiana University, IUPUI, Purdue University |
| NCT01447862 | Phase 4 | Oct 1, 2011 | University of Vienna |
| NCT01014741 | N/A | Oct 1, 2009 | Icahn School of Medicine at Mount Sinai, St. Jude Medical |
| NCT00589992 | N/A | Oct 1, 2007 | Ball Memorial Hospital, St. Jude Medical |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Indiana University | Academic/Hospital | 4 | 4 | 2 | 2013 |
| Purdue University | Academic/Hospital | 4 | 0 | 2 | 2013 |
| American Heart Association | Academic/Hospital | 3 | 0 | 2 | 2013 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 2 | 1 | 2009 |
| St. Jude Medical | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Ball Memorial Hospital | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| IUPUI | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Medtronic | For profit | 1 | 0 | 1 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2021 |
| University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2011 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Avet Lifesciences | For profit | MKTG | Apr 1, 2024 |
| Daiichi Sankyo | For profit | MKTG | Jan 11, 2010 |
| Lutipold | For profit | MKTG | Jan 11, 2010 |
| Mylan | For profit | MKTG | Jan 11, 2010 |
| PHARMOBEDIENT | For profit | MKTG | Jan 11, 2010 |
| Pfizer | For profit | MKTG | Dec 28, 1995 |
| Pfizer | For profit | NDA2 | Dec 28, 1995 |
| Pharmacia & Upjohn | For profit | NDA | Dec 28, 1995 |